Abstract The main goal of early phase trials is to gain knowledge about the clinical suitability of novel compounds, without pursuing specific therapeutic purposes. Healthy volunteers usually represent the ideal model for conducting phase I clinical trials, in order to investigate pharmacokinetics and pharmacodynamics as well as to document safety and tolerability without interference by concomitant pathological conditions. The increasing cost of novel drug development, in conjunction with ethical considerations, has fostered a new procedure for first-in-man trials, designated as "phase 0," which is conducted very early on a limited number of healthy volunteers who are exposed to low drug levels. The present review discusses issues concerning the enrollment of healthy volunteers in the early phase of drug development from different points of view, with some focus on the Italian experience. From the ethical standpoint, much discussion revolves around payments to healthy volunteers. Most authors agree that an adequate remuneration must be provided to healthy subjects, while avoiding coercion and excessive psychological pressure. Pending the lack of international and national guidelines, our center for clinical drug experimentation has implemented an operative procedure to estimate payments for healthy volunteers based on specific items, including restriction, time spent, discomfort, and risk. Other unresolved issues about the recruitment of healthy volunteers are represented by the lack of international consensus on the definition of healthy status and the need for guidelines about advertisement on clinical trials addressed to potential participants.
Introduction
The current model of clinical drug development is based on the division of clinical trials into four phases. In this framework, phase I traditionally represents the early stage of clinical drug development, and it is conducted to assess tolerability, to determine the possible therapeutic dose, to evaluate pharmacokinetics, and to obtain preliminary data on pharmacodynamics. Phase I begins with the first administration of a new compound in humans [1] .
Based on differences in the experimental design, different types of phase I trials can be usually distinguished: (1) Single ascending dose studies, in which small groups of subjects are given a single dose of the test drug, while they are observed and examined for a given period of time. If subjects do not experience any adverse effect, and the pharmacokinetic data are roughly consistent with predicted safe values, the dose is escalated, and a new group of subjects is then given a higher dose [2] . This stepping-up is continued until pre-calculated pharmacokinetic safety levels are reached, or intolerable side effects occur, indicating the point at which the drug appears to have reached the maximum tolerated dose [3] . The first dose of this phase I is a fraction of the dose that causes harm in animal testing. (2) Multiple ascending dose studies, conducted to better understand the pharmacokinetics and pharmacodynamics following repeated administration of the test drug at specific dose levels. (3) Short trials, designed to investigate variations in the absorption of the new drug following its oral administration in the presence of food.
The increasing cost of novel drug development, in conjunction with ethical considerations about the safety of first-in-man trials, has fostered the implementation of novel procedures with the purpose of optimizing, rationalizing, and enhancing the ability to eliminate redundancies in early phase clinical trials without compromising safety. Accordingly, a new procedure, designated as "phase 0," has been introduced in the very early stage of clinical drug development in order to gain insight into the clinical suitability of novel compounds before starting conventional phase I trials [4] .
Additional clinical studies, which are conducted in healthy volunteers, consist of bioequivalence pharmacokinetic experiments. To assess bioequivalence between two medicinal products containing the same active ingredient, such as a commercially available brand product and a generic product under clinical development, cross-over pharmacokinetic studies in healthy volunteers are currently regarded as the most suitable experimental approach [5] .
The present review focuses on issues concerning the enrollment of healthy volunteers in the early clinical phases of drug development from different points of view, including regulatory, normative, ethical, and logistical perspectives. This paper is also aimed at discussing the Italian experience concerning early phase clinical studies, which are scarcely represented in the national clinical research.
Definition of healthy volunteer
Defining a healthy volunteer is not easy, since different criteria underlying the concept of wellness can be implied in this condition. The Royal College of Physicians has defined the healthy volunteer as an "individual who is not known to suffer of any significant illness relevant to the proposed study, who should be within the ordinary range of body measurements, such as weight, and whose mental state is such that he is able to understand and give valid consent to the study" [6] . Moreover, in the Association of the British Pharmaceutical Industry guidelines for medical experiments in non-patient human volunteers, it is highlighted that the individual can not be expected to get therapeutic benefit from the proposed study [7] . The EMEA guideline also proposes a general definition of healthy volunteer for studies aimed at assessing pharmacokinetics: "healthy, adult volunteers, in well-defined and controlled conditions" [8] . On this basis, the selection of healthy volunteers is conducted by enrolling subjects without relevant pathologies and with organ functions, such as heart, liver and kidney, in the normal range. However, the general definitions of healthy volunteer, as proposed by current guidelines, allow wide margins of discretion. For example, might an asymptomatic subject with knee prosthesis or affected by inguinal hernia be considered eligible for a phase I clinical experimentation of a new antihypertensive drug? Moreover, might women under treatment with estrogen derivatives be eligible for early phases of drug experimentation? These simple examples support the notion that we can use different definitions of healthy subjects and that a critical judgment is required.
National and international regulations
Phase I of clinical drug development in healthy volunteers must be conducted in accordance with the general principles proposed for all clinical experimentations. In particular, the latest version of the Helsinki Declaration (2008) [9] , developed by the World Medical Association (WMA), comprises a set of ethical principles for the medical community regarding human experimentation, and it is widely regarded as the cornerstone document of human research ethics.
Good Clinical Practice (GCP) [10] is an international guideline indicating ethical and scientific standards of quality for designing, conducting, recording, and reporting all trials that involve the participation of human subjects, either patients or healthy volunteers. Compliance with the standards set by GCP provides public assurance that the rights, safety, and well-being of subjects enrolled in clinical trials are protected, consistently with principles established in the above-mentioned Declaration of Helsinki, and that the data yielded by clinical trials are reliable. In addition, the purpose of GCP is to provide a common standard for the European Union (EU), Japan, and U.S., thus facilitating the mutual acceptance of clinical data by the respective regulatory authorities.
The European guidelines, which must be met before, during, and after a phase I or bioequivalence clinical experimentation in healthy volunteers, include the following: (1) Nonclinical safety studies for the conduct of human clinical trials for pharmaceutical modification [11] . This guideline describes what preclinical tests, analyses or experiments on animal species must be performed from phase I to phase III prior to starting a human experimentation. (2) Strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products [12] . This guideline is intended to assist the transition from nonclinical to early clinical phases. (3) Pharmacokinetic studies in man [8] . This document defines the methods for performing a pharmacokinetic analysis in humans. (4) Addendum to the note for guidance on the investigation of bioavailability and bioequivalence: evaluation of bioequivalence of highly variable drugs and drug products [13] . This guideline indicates the requirements for bioavailability and bioequivalence studies, with particular regard for the design, conduction, evaluation, and reporting.
The Italian regulation of early clinical drug experimentation has been ratified in many decrees which have the force of law. As a member of the European Community, Italy must apply the regulation issued by the European Commission, Regulatory Agency for Clinical Experimentation. The Italian regulations mainly describe the rules underlying early clinical experimentation, with general indications concerning the organization, timing, privacy, etc., but they do not suggest the scientific methodology required for conducting first-inhuman clinical trials. In addition, they establish the minimum requirements for obtaining authority approval for early drug experimentation. These regulations also define some criteria for conducting clinical trials in healthy volunteers. In particular, a healthy volunteer is not allowed to enter a clinical study within 6 months of his last participation in a previous clinical experimentation, and it is responsibility of the chief of the clinical unit to hold a database of healthy volunteers who have been enrolled in phase I studies. Another important aspect, highlighted by the Italian regulations, is the respect for the privacy of participants.
Pharmacological classes of drugs studied in early phase clinical trials
As mentioned above, phase I clinical experimentation encompasses an array of studies that can be performed on healthy volunteers or patients and deal with the determination of a drug's tolerability and its pharmacodynamic/pharmacokinetic profile. In the setting of patients affected by a particular disease, these studies could include the evaluation of pharmacological activity, mainly for those drugs whose balance between expected therapeutic effect and toxicological risk might not justify their administration to healthy subjects. In particular, studies evaluating high-risk drugs should be performed in ill patients when the potential therapeutic effects of the test drug are expected to overcome its well known toxicity (e.g., antiblastic, anti-HIV drugs) or when the expected risks are not acceptable for healthy volunteers. These concepts have been widely accepted until recently, when the new "phase 0" or "early phase I" studies were introduced, according to which the so-called high risk drugs can be administered to a small number of healthy subjects in subtherapeutic micro-dosing studies, with a consequent reduction of toxicity risk. Therefore, phase 0 trials are not intended to replace the traditional dose escalation, safety, and tolerability studies, and they can not indicate whether a candidate drug will have a positive impact on the target disease [14] .
The scientific rationale underlying phase 0 trials includes determining as early as possible whether a new drug is capable of modulating the therapeutic target in humans and/or generating pharmacokinetic data, such as the biodistribution and metabolism. This early knowledge is critical in the process of drug development and it may avoid larger phase I and II trials for drugs shown to have unfavorable pharmacologic properties in phase 0 trials [15] . Considering the minimal amount of study drug administered in a phase 0 trial, international guidelines allow the participation of healthy volunteers in clinical studies evaluating toxic drugs. Moreover, phase 0 trials offer the opportunity of conducting bioavailability evaluations in healthy volunteers not only for well tolerated pharmacological classes, such as antiinflammatory, antihypertensive, antidiabetic, or antibiotic drugs, but also for new generations of antiblastics, antipsychotics, and antiepileptics [4, 16, 17] .
Healthy volunteer enrollment
From the industry standpoint, recruitment problems translate into potential revenue losses resulting from delays in bringing a new drug to the market [18] . Thus, clinical research units must ensure a fast recruitment of healthy volunteers into phase I studies, since an inadequate enrollment may increase the study costs, delay the time to completion, and possibly invalidate the trial outcome due to insufficient study power.
Recruiting volunteers is an unavoidable, often timeconsuming, and difficult task in clinical research [19] . Clinical pharmacological units may overcome recruiting problems by facilitating healthy volunteers' access to information about clinical experimentation. Internet advertising of clinical research studies can be accomplished in various ways, including websites dedicated to specific studies, clinical trial databases, which store basic information about studies, and direct email solicitation to target populations.
The U.S. Food and Drug Administration (FDA) requires that institutional review boards (IRB) examine and approve the advertising materials and methods used to recruit human subjects. Additionally, the FDA has issued a guidance regarding internet advertising. In particular, FDA does not require IRBs to review internet listings of clinical trials as long as the listings provide only "basic trial information" (e.g., study title, study summary, study location, contact information). Internet databases, which are designed with formal system limits (e.g., font size, font style, entry of only basic study information), satisfy this guidance, and thus, do not require IRB approval for each study listing.
Bramstedt [19] analyzed the incidence and nature of ethically inappropriate recruiting advertisements on the internet and provided descriptive guidance to researchers for responsible internet recruiting. The majority of advertisements satisfied the FDA guidance. However, 18% of them were ethically questionable with regard to font size, font style, and/ or verbiage. This author concluded that inappropriate recruiting advertisements can be coercive and misleading.
Healthy volunteer payment
The main goal of early phase trials is to gain knowledge about the clinical suitability of novel compounds, without pursuing specific therapeutic or diagnostic purposes, with the exception of circumstances described above (see section "Pharmacological classes of drugs studied in early phase clinical trials"). Innovative drugs, investigated in these early phases, could be harmful to the health of volunteers. Thus, it is reasonable to assume that altruism and idiosyncratic interests alone are unlikely to motivate a sufficient number of healthy subjects to act as volunteers in phase I trials. Without payments, recruitment can be slow, resulting in a thwarted and unfitting phase I. For these reasons, there is no doubt that an adequate remuneration must be offered to subjects recruited in early phase investigations. At the same time, coercion and excessive psychological influence should be avoided when obtaining consent [20] . For many years, an ethical-scientific debate has been ongoing to make decisions about fair payment of research subjects, as an attempt to compensate for their "lost wages" and "discomfort" due to their participation in clinical trials.
As in the U.S. and in other European countries, in Italy a detailed guideline or a specific law about research volunteer reimbursement is lacking (see section "National and international regulations"). Dickert et al. [20] reported that only 37.5% of clinical research organizations included in their analyses (academic research centers, pharmaceutical companies, contract research organizations, and independent institutional review boards) had written guidelines about the payment of subjects. These organizations disclosed that investigators and IRBs make decisions about payments and that both healthy and ill subjects in some studies are paid for reimbursement of their time, inconvenience, and travel, as an incentive, or for incurring risk. Moreover, Dickert et al. [20] underlined some methods adopted by different organizations to establish "how to pay" by specific formulas: payment for time by the hour, payment per inpatient day or outpatient visit, payment by a flat rate per day or visit, supplemental payment for the "inconvenience" associated with certain procedures. Overall, most organizations require that the estimated payment must be delivered to subjects as prorated (i.e., fractional payment based on the amount of time or procedures actually accomplished) rather than as a contingent payment at completion of the study [21] .
Several authors support the opportunity of a reimbursement to healthy volunteers [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] and propose different hypotheses to resolve this issue. Among the proposed ways, those indicated by Iltis et al. [21] and Resnick [29] appear to be quite interesting. Iltis et al. [21] underline the conflict existing between the practice of providing appropriate payments that avoid undue influence and the requirements of justice when recruiting normal healthy volunteers for phase I clinical trials. By keeping payments low intentionally, in line with recommendations by IRBs, investigators might target or systematically recruit healthy subjects from lower socio-economic levels, thus affecting social justice. On the other hand, higher reimbursements to volunteers might prompt more persons to enter clinical studies, while not discouraging the less well-off from enrollment. Although the investigators would likely prefer to achieve the goal of having a sufficient number of subjects, the latter method might appear as a wrong influencing procedure for the recruitment of research volunteers. An alternative way to decrease or increase payment homogeneously is to offer reimbursements based on various and personalized contributions, which may differ according to the specific procedures required from trial protocols [21] .
Resnick [29] describes five distinct models of payments to research subjects: (1) free market model: subjects are paid for providing services (such as completing surveys and undergoing tests and procedures), goods (such as blood, tissue or other biological samples), and to cover potential risks; (2) wage payment model: participants earn a wage equivalent to that of a typical unskilled labourer; (3) reimbursement model: in this setting, participation in clinical research is regarded as a public service (altruism) and volunteers can be paid to compensate for their travel expenses, lost wages, baby sitting expenses, etc.; (4) appreciation model: subjects are not compensated for the costs of participation, but they receive money or gifts, such as t-shirts, mugs, gift certificates, as a sign of the investigators' appreciation; (5) fair benefits model: subjects are neither paid labourers nor paid volunteers, but partners in research, sharing the benefits of research, including the economic ones.
The first two models represent a form of "compensated labour" and could motivate individuals to take part in a clinical trial merely to obtain consistent gains. By contrast, the remaining models reflect a "free and voluntary contribution" to community, but they can't embrace the actual motivations of healthy volunteers, who might be seeking free clinical tests or monetary gain [29] .
The lack of international and local guidelines about some crucial aspects related to the recruitment of healthy volunteers in early phase clinical trials, such as the definition of healthy status, payments, advertisement, and participation of the same subject in different experimentations, has prompted our center for clinical drug experimentation to implement specific operative procedures, attempting to properly address the following issues: (1) advertising to healthy volunteers for recruitment in early phase clinical trials after approval by the local ethics committee; (2) evaluation of the clinical and psychological status of a potential healthy volunteer; (3) creation of a database containing information on selected healthy subjects to be contacted for possible enrollment in a clinical trial, and allowing a proper monitoring of their participation in different experiments; (4) calculation of adequate reimbursements to healthy volunteers participating in clinical trials. The latter operative procedure is based on criteria which, although not yet fully comprehensive, provide a useful frame to estimate the amount of fair payment to healthy volunteers. In particular, it encompasses a number of items for which the amount of specific reimbursement is specifically indicated, e.g., number of blood samples; peripheral venous catheter or needle placement; number of clinical laboratory analyses performed during the screening and follow-up (blood and urine sampling, ECG, psychopathological test administration); other biological fluid sampling; restrictions imposed by a specific study protocol (for example, smoking and alcohol ban, physical exercise, etc.); investigational drug administration route (invasive: intramuscular, intravenous, by naso-gastric tube; not invasive: oral); filling in questionnaires and diaries; time spent at the clinical pharmacology center (per hour); discomfort or distress caused by study procedures (classified as minor, moderate, and major).
Discussion and conclusions
Interindividual variations in the responses to drugs are of major concern to both the physician and clinical pharmacologist, who should make efforts to provide, in the early phases of clinical development, as much information as possible on the tolerability and pharmacological activity (pharmacokinetics and pharmacodynamics) of new compounds [30] . In this respect, healthy volunteers usually represent the best model for conducting phase I clinical trials. By contrast, patients do not represent a suitable model for early phase studies, since they might be exposed to an increased risk associated with their clinical condition. Moreover, participants are not generally expected to receive any clinical benefit from their participation in a phase I clinical trial. Practical advantages resulting from the enrollment of healthy volunteers in the early phases of clinical drug experimentation consist of more rapid recruitment, possibility of simultaneous treatment, and greater suitability of healthy volunteers to learn complex procedures related to pharmacodynamic/pharmacokinetic investigations.
The enrollment of healthy volunteers in phase I clinical trials raises some ethical issues, particularly for treatments with drugs with high risk potential. Indeed, phase I studies aimed at determining the maximum tolerated dose or doselimiting toxicity of new compounds for treatment of cancer or HIV traditionally enroll patients in order to not expose healthy volunteers to the risks associated with harmful study drugs or high dose levels. In March 2006, TGN 1412, a new monoclonal antibody directed against a human lymphocytic antigen, which was studied in a first-in-man clinical trial at the Northwick Park Hospital of London, caused catastrophic systemic organ failure in healthy subjects (leading to the hospitalization of all six volunteers in intensive care units), despite being administered at a supposed sub-clinical dose of 0.1 mg per kg, which was about 500 times lower than that estimated as safe in animals [31] .
After the London tragedy, in an attempt to mitigate the risk associated with phase I clinical trials, the regulatory agencies, including EMEA, issued new guidelines to aid sponsors in the transition from nonclinical to early clinical drug development, including the "Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products" [32] and "Strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products" [12] . The first guideline provides criteria to classify new investigational medicinal products as potential high-risk medicinal products. The second one is intended to assist sponsors in the transition from nonclinical to early clinical development.
The increasing cost of drug development and the ethical needs for more careful safety procedures to be adopted for healthy volunteers in first-in-man trials have prompted the implementation of procedures with the purpose of optimizing, rationalizing, and enhancing the ability to eliminate redundancies in early phase clinical trials without compromising safety. These efforts have been collectively gathered under the slogan "New Safe Medicines Faster" in Europe and "The Critical Path" in the U.S. [2] . For these reasons a new procedure, designated as "phase 0," has been introduced in the very early stage of clinical drug development in order to gain early insights into the clinical suitability of novel compounds to shorten the duration of phase I studies. Phase 0 trials are clinical studies conducted very early in phase I, just before the traditional dose escalation, safety, and tolerability studies. These first-in-man trials should involve a very limited number of healthy volunteers or patients who are being exposed to a novel compound at low dose for a short time period, as compared to the starting doses of phase I. Subjects enrolled in phase 0 clinical trials have no therapeutic or diagnostic expectations. In principle, the trials should allow investigators to quickly establish whether a novel compound has appropriate pharmacokinetic and pharmacodynamic profiles in humans [4, 16, 17] .
Based on the widespread scientific literature, providing a suitable reimbursement to volunteers recruited in clinical trials appears to be mandatory. As sanctioned by Italian regulations, the investigator is under the obligation of communicating to the Ethics Committee "the potential compensation for covering every active expense, when provided for" and "the procedures to afford a reimbursement for loss of income, only in the case of healthy volunteers." However, current Italian laws do not describe or suggest any parameter to evaluate the extent and limits of reimbursements to healthy volunteers. Thus, the Italian investigators and ethics committees currently represent the two "authorities" who retain in their hands the responsibility for evaluating the adequacy of payments proposed by clinical trial promoters.
In conclusion, some issues about healthy volunteer recruitment in first-in-man trials and reimbursement remain unresolved, and they can be summarized as follows: (1) There is a lack of international consensus on the definition of healthy status, based on standard physical, psychological, and laboratory parameters, suitable for the enrollment of candidate subjects in first-in-man trials. (2) There is a need for guidelines about appropriate advertisements addressed to potential participants in first-in-man clinical trials, to set out specific ethical limitations. (3) There is a lack of international and/or local statements about standard criteria for offering fair payments to healthy volunteers enrolled in first-in-man trials. (4) Based on current Italian regulations, there is a need for a national register to monitor the participation of healthy subjects in different early clinical trials at the same or different centers for drug experimentation. (5) In view of a "new era of early phase trials," the national legislation should offer Italian investigators conducting phase 0 and phase I trials a comprehensive guideline encompassing all principles sanctioned by EMEA guidelines.
